Vertex Pharmaceuticals Incorporated (VRTX) Q3 2017 Earnings Results

Vertex Pharmaceuticals Beats on EPS, Stock Down 2.85%

Vertex Pharmaceuticals reported a strong EPS that beat expectations, indicating solid financial performance. However, the stock fell by 2.85% following the earnings report, likely due to the lack of revenue details and future guidance. Investors may be cautious as they await more information on the company's outlook.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.53	N/A	+41.71%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting strong operational performance. However, they did not offer any guidance for future earnings.

The company is pleased with the EPS performance this quarter.

Management did not provide specific guidance for future quarters.

Vertex Pharmaceuticals Beats on EPS, Stock Down 2.85%

Key numbers

Management commentary

Vertex Pharmaceuticals Incorporated

More earnings this week

Vertex Pharmaceuticals Beats on EPS, Stock Down 2.85%

Key numbers

Management commentary